Published in Cancer Res on July 06, 2011
Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep (2014) 0.98
Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget (2015) 0.92
Regulation of C-X-C chemokine gene expression by keratin 17 and hnRNP K in skin tumor keratinocytes. J Cell Biol (2015) 0.90
CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer (2015) 0.83
Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prev Res (Phila) (2015) 0.83
Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells. Cancer Res (2016) 0.79
CXCR3 May Help Regulate the Inflammatory Response in Acute Lung Injury via a Pathway Modulated by IL-10 Secreted by CD8 + CD122+ Regulatory T Cells. Inflammation (2016) 0.76
Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. Oncotarget (2015) 0.75
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med (1998) 7.24
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 5.07
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 4.41
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol (2011) 3.73
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc (2009) 3.14
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res (2002) 2.20
Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 1.99
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage. Cancer Res (2007) 1.57
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A (1996) 1.52
The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med (2003) 1.51
Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 1.49
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest (2007) 1.46
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008) 1.40
IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res (2009) 1.39
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor. Am J Pathol (2007) 1.38
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A (2007) 1.26
Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22
Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Am Physicians (1998) 1.19
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res (2009) 1.17
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol (2009) 1.12
Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res (2008) 1.08
Lack of CXC chemokine receptor 3 signaling leads to hypertrophic and hypercellular scarring. Am J Pathol (2010) 1.07
The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther (2004) 1.06
Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta (2006) 1.04
Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate (2006) 0.98
Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. J Invest Dermatol (2009) 0.95
Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer (2008) 0.91
Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res (2009) 0.89
Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol (2009) 0.86
CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. J Am Acad Dermatol (2008) 0.85
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol (2006) 4.87
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet (2003) 3.95
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res (2006) 2.56
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck (2011) 2.30
Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature (2012) 2.25
The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med (2003) 2.20
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
MR imaging of the spleen: spectrum of abnormalities. Radiographics (2005) 2.16
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol (2007) 2.05
Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother (2005) 2.05
Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest (2003) 2.02
Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol (2005) 2.01
Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol (2010) 2.01
High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2011) 2.00
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 1.99
CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity (2011) 1.99
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature (2008) 1.88
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy (2003) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75
Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet (2006) 1.74
Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother (2005) 1.69
Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med (2009) 1.67
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother (2008) 1.67
Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol (2011) 1.61
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe (2012) 1.54
A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy. J Urol (2008) 1.49
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol (2010) 1.45
Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity (2006) 1.44
Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope (2010) 1.42
Interferon-gamma and cancer immunoediting. Immunol Res (2005) 1.41
Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med (2011) 1.39
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
Adrenal masses: mr imaging features with pathologic correlation. Radiographics (2004) 1.38
Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope (2009) 1.37
IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol (2002) 1.36
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1.34
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood (2008) 1.33
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol (2005) 1.33
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother (2012) 1.31
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol (2006) 1.31
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am J Pathol (2002) 1.28
Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med (2005) 1.26
A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog (2011) 1.26
A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice. J Immunol (2008) 1.23
Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol (2013) 1.18
MRI of adrenal and extraadrenal pheochromocytoma. AJR Am J Roentgenol (2005) 1.16
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol (2007) 1.12
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer (2012) 1.11
Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol (2008) 1.11
Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy (2011) 1.10
Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. J Virol (2012) 1.09
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09
Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer (2011) 1.09
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother (2012) 1.07
Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. Arch Otolaryngol Head Neck Surg (2011) 1.07
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res (2012) 1.06
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol (2009) 1.05
Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med (2010) 1.05
Breaking down the barriers to cancer immunotherapy. Nat Immunol (2005) 1.04
Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod Pathol (2011) 1.04
Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol (2012) 1.03
Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis (2005) 1.03